Shang Luo Shi

Researchers are evaluating ursodeoxycholic acid as a potential treatment for gastric intestinal metaplasia IM in adults who do not have Helicobacter pylori infection. This Phase 4 clinical trial aims to understand if ursodeoxycholic acid can help reverse IM and to assess any medical problems participants may experience while taking the medication. The study compares ursodeoxycholic acid to a placebo to determine its impact on this stomach condition. Participants are randomly assigned to one of two groups. One group takes oral ursodeoxycholic acid capsules at a dose of 250 mg three times daily for six months, while the other group takes matching placebo capsules at the same dose and schedule. Participants visit the clinic every four weeks for checkups, symptom evaluations, and to receive their medication supply. During the study, participants undergo assessments including upper gastrointestinal endoscopy and histopathological examinations to monitor changes in gastric intestinal metaplasia and gastric atrophy stages. Researchers measure the regression and progression rates of these conditions based on OLGIM and OLGA staging from enrollment through the six-month treatment period. Safety and any side effects are also closely monitored throughout the trial.